A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discovery

Molecular and Cellular Proteomics

Volumn 7, Issue 3, 2008, Pages 509-518

  Villanueva, Josep ^a   Nazarian, Arpi ^a   Lawlor, Kevin ^a   Yi, San San ^a   Robbins, Richard J ^b   Tempst, Paul ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EXOPEPTIDASE;

ADSORPTION; ANALYTIC METHOD; ARTICLE; AUTOMATION; CONTROLLED STUDY; COVARIANCE; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME SUBSTRATE; FUNCTIONAL PROTEOMICS; HEMOSTASIS; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLITE; METASTASIS POTENTIAL; MULTIVARIATE ANALYSIS; PEPTIDOMICS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PROCESSING; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SEQUENCE SPECIFIC EXOPEPTIDASE ACTIVITY TEST; STANDARD; THYROID CANCER;

AMINO ACID SEQUENCE; CASE-CONTROL STUDIES; EXOPEPTIDASES; HUMANS; KINETICS; MOLECULAR SEQUENCE DATA; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PEPTIDES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 41549158639     PISSN: 15359476     EISSN: None     Source Type: Journal    
DOI: 10.1074/mcp.M700397-MCP200     Document Type: Article

References (43)

1. Washbum, M. P., Wolters, D., and Yates, J. R., III (2001) Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 19, 242-247
2. Qian, W. J., Jacobs, J. M., Liu, T., Camp, D. G., II, and Smith, R. D. (2006) Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol. Cell. Proteomics 5, 1727-1744
3. Jensen, O. N. (2DO4) Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry. Curr, Opin. Chem. Biol. 8, 33-41
4. Petricoin, E. F., Belluco, C., Araujo, R. P., and Liotta, L. A. (2006) The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat. Rev. Cancer 6, 961-967
5. Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., and Walter, P. (2002) Molecular Biology of the Cell, 4th Ed., Garland Science, New York
6. Kobe, B., and Kemp, B. E. (1999) Active site-directed protein regulation. Nature 402, 373-376
7. Sidransky, O. (2002) Emerging molecular markers of cancer. Nat. Rev. Cancer 2, 210-219
8. Greenbaum, D., Baruch, A., Hayrapetian, L, Darula, Z., Burlingame, A., Medzihradszky, K. F., and Bogyo, M. (2002) Chemical approaches for functionally probing the proteome. Mol. Cell. Proteomics 1, 60-68
9. Kato, D., Boatright, K. M., Berger, A. B., Nazif, T., Blum, G., Ryan, C., Chehade, K. A., Salvesen, G. S., and Bogyo, M. (2005) Activity-based probes that target diverse cysteine protease families. Nat. Chem. Biol. 1, 33-38
10. Adam, G. C., Sorensen, E. J., and Cravatt, B. F. (2002) Proteomic profiling of mechanistically distinct enzyme classes using a common chemotype. Nat. Biotechnol. 20, 805-809
11. Jessani, N., Niessen, S., Wei, B. Q., Nicolau, M., Humphrey, M., Ji, Y., Han, W., Noh, D. Y., Yates, J. R., III, Jeffrey, S. S., and Cravatt, B. F. (2005) A streamlined platform for high-content functional proteomics of primary human specimens. Nat. Methods 2, 691-697
12. Schrader, M., and Selle, H. (2006) The process chain for peptidomic biomarker discovery. Dis. Markers 22, 27-37
13. Tammen, H., Zucht, H. D., and Budde, P. (2007) Oncopeptidomics - a commentary on opportunities and limitations. Cancer Lett. 249, 80-86
14. Diamandis, E. P. (2007) Oncopeptidomics: a useful approach for cancer diagnosis? Clin. Chem. 53, 1004-1006
15. DeClerck, Y. A., Mercurio, A. M., Stack, M. S., Chapman, H. A., Zutter, M. M., Muschel, R. J., Raz, A., Matrisian, L. M., Sloane, B. F., Noel, A., Hendrix, M. J., Coussens, L., and Padarathsingh, M. (2004) Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am. J. Pathol. 164, 1131-1139
16. Puente, X. S., Sanchez, L. M., Overall, C. M., and Lopez-Otin, C. (2003) Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet 4, 544-558
17. Villanueva, J., Shaffer, D. R., Philip, J., Chaparro, C. A., Erdjument-Bromage, H., Olshen, A. B., Fleisher, M., Lilja, H., Brogi, E., Boyd, J., Sanchez-Carbayo, M., Holland, E. C., Cordon-Cardo, C., Scher, H. I., and Tempst, P. (2006) Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Investig. 116, 271-284
18. Rickles, F. R., and Edwards, R. L. (1983) Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 62, 14-31
19. Bick, R. L. (1992) Coagulation abnormalities in malignancy: a review. Semin. Thromb. Hemost. 18, 353-372
20. Green, K. B., and Silverstein, R. L. (1996) Hypercoagulability in cancer. Hematol. Oncol. Clin. N. Am. 10, 499-530
21. Villanueva, J., Philip, J., Chaparro, C. A., Li, Y., Toledo-Crow, R., DeNoyer, L., Fleisher, M., Robbins, R. J., and Tempst, P. (2005) Correcting common errors in identifying cancer-specific serum peptide signatures. J. Proteome Res. 4, 1060-1072
22. Villanueva, J., Martorella, A. J., Lawlor, K., Philip, J., Fleisher, M., Robbins, R. J., and Tempst, P. (2006) Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol. Cell. Proteomics 5, 1840-1852
23. Casteels, P., Romagnolo, J., Castle, M., Casteels-Josson, K., Erdjument-Bromage, H., and Tempst, P. (1994) Biodiversity of apidaecin-type peptide antibiotics. Prospects of manipulating the antibacterial spectrum and combating acquired resistance. J. Biol. Chem. 269, 26107-26115
24. Castle, M., Nazarian, A., Yi, S. S., and Tempst, P. (1999) Lethal effects of apidaecin on Escherichia coli involve sequential molecular interactions with diverse targets. J. Biol. Chem. 274, 32555-32564
25. Villanueva, J., Lawlor, K., Toledo-Crow, R., and Tempst, P. (2006) Automated serum peptide profiling. Nat. Protoc. 1, 880-891
26. Villanueva, J., Philip, J., DeNoyer, L., and Tempst, P. (2007) Data analysis of assorted serum peptidome profiles. Nat. Protoc. 2, 588-602
27. Villanueva, J., Philip, J., Entenberg, D., Chaparro, C. A., Tanwar, M. K., Holland, E. C., and Tempst, P. (2004) Serum peprtide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal. Chem. 76, 1560-1570
28. Anderson, L., and Hunter, C. L. (2006) Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 5, 573-588
29. Bamidge, D. R., Goodmanson, M. K., Klee, G. G., and Muddiman, D. C. (2004) Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-MS/MS using protein cleavage and isotope dilution mass spectrometry. J. Proteome Res. 3, 644-652
30. Gerber, S. A., Rush, J., Stemman, O., Kirschner, M. W., and Gygi, S. P. (2003) Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl. Aced. Sci. U. S. A. 100, 6940-6945
31. Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B., Steen, H., Pandey, A., and Mann, M. (2002) Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 1, 376-386
32. Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H., and Aebersold, R. (1999) Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17, 994-999
33. Koomen, J. M., Li, D., Xiao, L. C., Liu, T. C., Coombes, K. R., Abbruzzese, J., and Kobayashi, R. (2005) Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J. Proteome Res. 4, 972-981
34. Matrisian, L. M., Sledge, G. W., Jr., and Mohla, S. (2003) Extracellular proteolysis and cancer: meeting summary and future directions. Cancer Res. 63, 6105-6109
35. Check, E. (2004) Proteomics and cancer running before we can walk? Nature 429, 496-497
36. Diamandis, E. P. (2004) Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol. Cell. Proteomics 3, 367-378
37. Nand, S., Fisher, S. G., Salgia, R., and Fisher, R. I. (1987) Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. J. Clin. Oncol. 5, 1998-2003
38. Rickles, F. R., Levine, M., and Edwards, R. L. (1992) Hemostatic alterations in cancer patients. Cancer Metastasis Rev. 11, 237-248
39. Goldsmith, G. H. (2001) Hemostatic changes in patients with malignancy. Int. J. Hematol. 73, 151-156
40. Davis, M. T., and Patterson, S. D. (2007) Does the serum peptidome reveal hemostatic dysregulation? Ernst Schering Res. Found. Workshop 61, 23-44
41. Jandl, J. H. (1996) Blood: Textbook of Hematology, Little, Brown and Go., New York
42. Stamatoyannopoulos, G., Majerus, P. W., Perlmutter, R. M., and Varmus, H. (2001) The Molecular Basis of Blood Diseases, 3rd Ed., W. B. Saunders Co., Philadelphia
43. Marx, P. F. (2004) Thrombin-activatable fibrinolysis inhibitor. Curr. Med. Chem. 11, 2335-2348